Adaptive Trial Design for Faster Development
Biotechs can accelerate progression from Phase I to Phase II through early patient inclusion, integrated regulatory planning, and seamless CRO partnerships.
Ben Edwards, COO of Avance Clinical, discussed common biotech challenges, emphasizing the need to address preclinical package gaps and obtain patient data early.
He highlighted the importance of CROs with deep scientific capabilities to create a sound scientific argument for new drugs.
Edwards noted the shift towards adaptive trial designs and the benefits of continuity with the same CRO, requiring integrated teams and data visualization.
Author's summary: Adaptive trial design accelerates biotech development.
- Early patient inclusion
- Integrated regulatory planning
- Seamless CRO partnerships